TSXV:IPCI.H - Post by User
Post by
Dollarpeeon May 12, 2019 6:30pm
199 Views
Post# 29739715
$268M in Sales + FDA Approval = $1++
$268M in Sales + FDA Approval = $1++Dr. Isa Odidi, CEO of Intellipharmaceutics, stated, "We have achieved yet another milestone and believe that this approval demonstrates the Company's ability to successfully take product candidates from development to regulatory approval."
According to Symphony Health Solutions Corporation, sales in the United States for the 12 months ended March 2019 of Pristiq(R) and all generic equivalents, were approximately $268 Million (in TRx MBS Dollars), which represents projected new and refilled prescriptions representing a standardized dollar metric based on manufacturer's published catalog or list prices to wholesalers and does not represent actual transaction prices and does not include prompt pay or other discounts, rebates or reductions in price.
Several other generic versions of this product are currently available in the market. There can be no assurance that the Company's desvenlafaxine extended-release 50 mg, and 100 mg tablets will be successfully commercialized and produce significant revenue for us.